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Disparate Cytotoxic Activity of Nickel-Specific CD8 and
CD4 T Cell Subsets Against Keratinocytes1
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Allergic contact dermatitis (ACD) is the result of an exaggerated immune reaction to haptens mediated by skin-homing T cells,
but the effector mechanisms responsible for the tissue damage are poorly understood. Here we studied the capacity of distinct
subsets of hapten-specific T cells to induce apoptosis in autologous keratinocytes. Skin- and blood-derived nickel-specific CD8 T
cytotoxic 1 (Tc1) and Tc2 clones as well as CD4 Th1 and Th2 expressed the cutaneous lymphocyte-associated Ag and exhibited
strong MHC-restricted cytotoxicity against nickel-coupled B lymphoblasts, as detected by the [3H]TdR release assay. Both Tc1 and
Tc2 clones, but not CD4 T cells, displayed a significant cytotoxic activity against resting nickel-modified keratinocytes. Following
IFN- treatment, keratinocytes expressed MHC class II and ICAM-1 and became susceptible to Th1-mediated, but not Th2-
mediated, cytotoxicity. The molecules of the two major cytotoxic pathways, Fas ligand (FasL) and perforin, were expressed by Tc1,
Tc2, and Th1 cells, whereas Th2 cells expressed only FasL. Experiments performed in the presence of specific inhibitors of the
perforin (concanamycin A) and FasL (brefeldin A) pathway indicated that perforin-mediated killing dominated in Tc1 and Tc2,
and FasL-mediated cytotoxicity prevailed in Th2 clones, with a more heterogeneous behavior in the case of Th1 cells. Finally,
perforin mRNA was expressed in ACD lesional skin, as assessed by RT-PCR analysis. In aggregate, our results indicate that
keratinocytes can be target of multiple hapten-specific CTL responses, that may have distinct roles in the epidermal injury during
ACD.                                           
A llergic contact dermatitis (ACD)
3 is a common skin dis-
ease that is due to an exaggerated T cell response to
highly reactive small m.w. haptens (1, 2). Sensitization
occurs when haptens penetrating the skin are picked up by den-
dritic cells and carried to the regional lymph nodes, where MHC-
hapten complexes are presented to naive T cells (3, 4). Clonally
expanded hapten-specific T cells acquire a propensity to recircu-
late in the skin and are rapidly activated following Ag challenge.
Despite considerable progress in understanding the development
of hapten-specific immunity, less is known about the mechanisms
responsible for the tissue injury during ACD. Characteristic his-
tologic features of the disease include epidermal intercellular
edema (spongiosis), keratinocyte damage, and the presence of an
infiltrate of T cells, monocytes, and dendritic cells in the dermis
and epidermis. Early ultrastructural studies of ACD revealed dam-
aged keratinocytes in close contact to mononuclear cells (5), sug-
gesting a role for T cell-mediated cytotoxicity in the expression of
the disease, in line with other investigations on murine contact
hypersensitivity (CH) (6, 7). It has been recently shown that P0/0
gld mice lacking Fas ligand (FasL) and perforin genes, both of
which are involved in T cell-mediated cytotoxicity, fail to mount
CH reactions (8). In parallel, evidence has been provided that hap-
ten-specific CD8 T cells have a crucial effector role in murine CH
(9–11). In humans, a link between the high frequency of specific
CD8 T cells in peripheral blood and the development of ACD has
been suggested (12, 13), but few studies have characterized hap-
ten-specific CD8 T cells (12–15). In contrast, in both mice and
humans discrete hapten-specific CD4 T cell populations have
been identified, which may play distinct roles in the course of the
disease. Th1 cells, producing high amounts of IFN- and TNF- ,
display predominant effector functions (16, 17) and may cooperate
with CD8 T cells in amplifying the inflammatory response. Stud-
ies aimed at defining the role of Th2 cells, releasing IL-4 but not
IFN- , provided conflicting results, with some indicating a sup-
pressive (18 19) and others an enhancing or no effect on CH (20,
21). Finally, IL-10-producing CD4 T regulatory 1 lymphocytes
seem to be primarily involved in the regulation of ACD by inhib-
iting the maturation and functions of dendritic cells (22).
Keratinocytes are profoundly involved in the elicitation and ef-
fector phase of ACD, because they secrete cytokines and chemo-
kines that effectively activate resident dendritic cells and endothe-
lial cells and contribute to lymphocyte recruitment into the skin
(17, 23–25). Keratinocytes, under the influence of lymphocyte-
derived cytokines such as IFN- and IL-17, also express MHC
class II and adhesion molecules (ICAM-1) crucial for T cell func-
tion and retention in the epidermis (17, 26). Moreover, IFN- up-
regulates Fas expression and renders keratinocytes sensitive to
Fas-mediated lysis (27, 28).
In this study we investigated the capacity of nickel-specific
CD8 and CD4 T cells to induce keratinocyte apoptosis and the
pathways of target cell injury. Although both type 1 and type 2
nickel-reactive CD8 and CD4 T cells were cytotoxic against B
lymphoblasts, resting keratinocyte were killed exclusively by
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CD8 T lymphocytes. IFN- treatment rendered keratinocytes
susceptible to Th1, but not Th2, cytotoxicity. These results indicate
that T cell killing of keratinocytes can have an important role in
mediating the epidermal damage during ACD and emphasize the
role of CD8 T cells in the expression of the disease.
Materials and Methods
Patients
Patients (n 3) included in the study had a history of eczematous der-
matitis after contact with metals and a positive reaction to epicutaneous
application of 5% NiSO4 in petrolatum on the back under occlusion. They
had not taken any medication for at least 15 days before skin and blood
donation. Patients were enrolled in the study after written informed con-
sent, and the study was approved by the Istituto Dermopatico
dell’Immacolata ethical committee.
Abs and reagents
The mAbs anti-CD4 (SK1, IgG1) and anti-CD28 (Leu-28, IgG1) were
purchased from Becton Dickinson (San Jose, CA). Anti-CD3 (UCHT-1,
IgG1 azide free) mAb was obtained from Immunotech (Marseilles,
France), and anti-MHC class I (W6/32, IgG1) from Dako (Glostrup, Den-
mark). The mAbs anti-CD8 (Leu 2a, IgG1), anti-HLA-DR (G46-6, IgG1),
anti-CD54 (HA58, IgG1), anti-Bcl-2 (4D7, IgG1), anti-perforin ( G9,
IgG2b), anti-Fas (ZB4, IgG1), anti-FasL (NOK-1, IgG1), and anti-
cutaneous lymphocyte-associated Ag (CLA; HECA-452, rat IgM) were
purchased from PharMingen (San Diego, CA). Control unconjugated
mouse IgG1 and IgG2b were obtained from Becton Dickinson, and rat IgM
from PharMingen (San Diego, CA). The FITC-conjugated goat anti-mouse
Ig and anti-rat IgM were purchased from Southern Biotechnology Asso-
ciates (Birmingham, AL) and PharMingen, respectively. Recombinant hu-
man IFN- and TNF- were provided by Genzyme (Cambridge, MA).
Concanamycin A (CMA) and brefeldin A (BFA) were purchased from
Sigma-Aldrich (Milan, Italy).
Nickel-specific T cell lines and clones
PBMC from nickel-allergic patients were separated by centrifugation over
Ficoll-Hyperpaque (Lymphoprep, Nycomed-Pharma, Oslo, Norway) and
left to adhere (6 106 cells/ml) in petri dishes for 2 h at 37°C in RPMI
1640 supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 1%
nonessential amino acids, 0.05 mM 2-ME, 100 U/ml penicillin, 100 g/ml
streptomycin (all from Life Technologies, Chagrin Falls, OH; complete
RPMI), and 5% human serum. The nonadherent fraction was depleted of
CD19 , HLA-DR , and CD8 or CD4 cells by incubation with immu-
nomagnetic beads coated with specific mAbs (Dynabeads M450, Dynal,
Oslo, Norway) to obtain 95% pure CD4 and CD8 T cells, respec-
tively. For isolating T cells from lesional skin, biopsies from 48-h positive
patch test reactions to NiSO4 were extensively washed and placed in com-
plete RPMI supplemented with 5% human serum and 30 U/ml rhIL-2 (pro-
vided by Chiron Italia, Milan, Italy). Medium was replaced every third day,
and T cells emigrated from tissue samples were collected on day 12 and
then cultured with irradiated autologous PBMC and 20 g/ml NiSO4 (Sig-
ma) to enrich for nickel-specific T lymphocytes. T cell lines were cloned
by limiting dilution (0.5 cells/well in 96-well U-bottom microplates) in
complete RPMI plus 10% heat-inactivated FBS in the presence of 2 105
irradiated PBMC, 30 U/ml IL-2, and 1% PHA (Life Technologies). Clones
were grown by adding IL-2 (30 U/ml) twice a week and were periodically
stimulated with either 1% PHA in the presence of feeder cells or plate-
coated anti-CD3 (1 g/ml) and soluble anti-CD28 (1 g/ml) mAbs. The
nickel reactivity of both T cell lines and clones was assayed in proliferation
assays as previously described (12). The pattern of cytokines released by T
cell clones (Tcc) was evaluated on supernatants after 48-h activation with
immobilized anti-CD3 and soluble anti-CD28, using commercially avail-
able ELISA kits (R&D Systems, Minneapolis, MN).
Keratinocyte cultures and B cell lines
Epidermal sheets were obtained from the roof of suction blisters raised on
normal skin of the forearms of nickel-allergic patients and disaggregated to
single-cell suspensions using 0.5% trypsin (Biochrom, Berlin, Germany).
Keratinocyte primary cultures were established by seeding epidermal cells
(1.2–2 104 cells/cm2) on a feeder layer of irradiated 3T3/J2 fibroblasts
(2 104 cell/cm2) and were cultured in modified Green’s medium as
described previously (17). At 70– 80% confluence, keratinocytes were de-
tached with 0.05% trypsin and 0.02% EDTA, aliquoted, and cryopreserved
in liquid nitrogen. Second- or third-passage keratinocytes were used as
target cells in the cytotoxicity assay, with cells cultured in serum-free me-
dium (keratinocyte growth medium, Clonetics, San Diego, CA) without
hydrocortisone for at least 3 days before experiments were performed.
Keratinocytes were treated, or not, with 300 U/ml IFN- alone or in com-
bination with TNF- (50 g/ml) for at least 24 h and extensively washed
before use in the cytotoxicity tests. Autologous B lymphoblastoid cell lines
(B-LCL) were generated according to standard procedures by incubating
PBMC with supernatant from the EBV-producing marmoset line B95/8
(American Type Culture Collection, Manassas, VA) in the presence of 2
g/ml cyclosporin A for 7–15 days.
Cytotoxicity assay
To identify DNA fragmentation induced by nickel-specific Tcc in autolo-
gous B-LCL or keratinocytes the [3H]TdR release assay was employed as
previously described (29). B-LCL and keratinocytes were preincubated
with 5 Ci/ml [3H]TdR (Amersham, Little Chalfont, U.K.) at 37°C for 10
and 16 h, respectively, and seeded at 2–3 104/well in round-bottom
microtiter plates in complete RPMI supplemented with 10% FBS. Effector
T cells used in the cytotoxic assays were devoid of contaminating CD19 ,
CD14 and CD1a cells, as assessed by FACS analysis (data not shown).
Effector cells were cocultured with target cells for 5 h in the presence or the
absence of 20 g/ml NiSO4. Spontaneous release of [
3H]TdR by target
cells was evaluated in wells containing medium alone. Cells were har-
vested on fiber-coated 96-well plates (Packard Instruments, Groningen,
The Netherlands), and radioactivity was measured in a Topcount (Packard
Instruments). The percentage of lysis was calculated as [(cpm without T
cells cpm with T cells)/cpm without T cells) 100]. Specific lysis was
determined by subtracting the percentage of lysis obtained in the absence
of NiSO4 from that measured in the presence of NiSO4. Unspecific lysis
was always 3%. For blocking experiments with mAbs, target cells were
preincubated at 4°C for 30 min with the relevant mAb (anti-MHC-I and
anti-HLA-DR, 1 g/ml; anti-ICAM-1, 10 g/ml) and then used in the
[3H]TdR release assay. Where indicated, Tcc were preincubated with
0–200 nM CMA or 0–50 M BFA for 2 h and assayed for cytotoxicity in
the presence of the drug as described previously (30).
Flow cytometry
Cells were examined by flow cytometry using nonconjugated primary
mAbs followed by the appropriate secondary FITC-conjugated Ig. In con-
trol samples, staining was performed using isotype-matched control Ig.
Expression of FasL, perforin, and Bcl-2 was determined after fixation with
2% paraformaldehyde and permeabilization with 0.5% saponin. Intracel-
lular FasL expression directly correlates with the levels of the extracellular
form, which is rapidly cleaved by metalloproteinases (31, 32) and thus
hardly detected. Cells were analyzed with a FACScan equipped with
CellQuest software (Becton Dickinson, Mountain View, CA).
RT-PCR analysis
Total cellular RNA was extracted from skin samples using the acid gua-
nidinium thiocyanate-phenol-chloroform method (33). RNA (1 g) was
reverse transcribed to cDNA using oligo(dT) primers and then amplified
with GeneAmp RNA PCR kit (Perkin-Elmer, Roche Molecular Systems,
Branchburg, NJ) according to the manufacturer’s protocol. The following
synthetic oligonucleotides were used: for perforin, 5 -GTCTGCTCCTC
CTGGGCATCCTTC-3 and 5 -CGGGGGAGTGTGTACCACATGGAAA-3
(589-bp amplification product); for IFN- , 5 -TGCAGGTCATTCAGATGTAG
3 , and 5 -AGCCATCACTTGGATGAGGG-3 (306-bp amplification product);
and for IL-4, 5 -GCCTGTTGTACCAGCTGGTTTTTC-3 and 5 -TGAC
CCCTGAGCATCCTGGATTAT-3 (308-bp amplification product). As a
control, the -actin gene was used with primers 5 -TGACGGGGTCAC
CCACACTGTGCCCATCTA-3 and 5 -CTAGAAGCATTTGCGGTG
GACGATGGAGGG-3 (631-bp amplification product).
Results
Cytokine pattern and immunophenotype of nickel-specific CD4
and CD8 Tcc
CD4 and CD8 Tcc were isolated from the blood and lesional
skin of patients with ACD to nickel and were characterized for Ag
specificity and cytokine release as well as expression of the CLA
and molecules mediating cytotoxicity (Table I). Both skin- and
blood-derived CD4 and CD8 nickel-specific Tcc were positive
for CLA, indicating their ability to recirculate in the skin environ-
ment (12, 23, 24), and expressed FasL upon activation, as detected
by FACS analysis (Table I and Fig. 1). Perforin was constitutively






















expressed in all CD8 independent of their cytokine pattern and in
CD4 clones with a Th1 phenotype, whereas Th2 cells were in-
variably negative both in resting conditions (not shown) and after
activation (Fig. 1).
Both CD4 and CD8 nickel-specific clones kill autologous
B-LCL, but show disparate cytotoxic capacity against
autologous keratinocytes
The cytotoxic potential of both type 1 (Th1 and Tc1) and type 2
(Th2 and Tc2) nickel-specific T lymphocytes was evaluated with
the [3H]TdR release assay, because it detects cleaved DNA in tar-
get cells and thus directly correlates to cell apoptosis (29, 34). Both
Tc1 and Tc2 clones exhibited comparable cytotoxic activity
against autologous B-LCL in the presence of NiSO4 (Fig. 2). Sim-
ilarly, Th1 clones demonstrated strong cytotoxicity against nickel-
loaded B-LCL, whereas Th2 clones were less potent (Fig. 3). Non-
stimulated keratinocytes were killed less efficiently than B-LCL by
CD8 cells, and IFN- pretreatment of keratinocytes variably en-
hanced the lytic activity of some Tc1, but none of the Tc2, clones
(Fig. 2). In contrast, Th1 clones exhibited a poor or absent cyto-
toxic activity against resting keratinocytes (Fig. 3), and significant
Th1-mediated apoptosis was observed only in keratinocytes pre-
viously activated with IFN- . Finally, Th2 clones, although being
FIGURE 1. FACS analysis of perforin and FasL expression in repre-
sentative nickel-specific Th1, Th2, Tc1, and Tc2 clones. Tcc were stimu-
lated for 48 h with immobilized anti-CD3, fixed, permeabilized, and then
stained with mouse anti-human perforin or anti-FasL mAb ( ). , Cells
stained with isotype-matched mouse Ig.
FIGURE 2. CD8 nickel-specific clones exert cytotoxic activity against
B-LCL and keratinocytes. Target cells were B-LCL ( ), unstimulated ker-
atinocytes ( ), and IFN- -pretreated keratinocytes ( ). Cytotoxicity was
determined using the [3H]TdR release assay. Specific killing was calcu-
lated as described in Materials and Methods. Unspecific killing was always
3%.
Table I. Characteristics of the nickel-specific Tcc used in the study
Clone Origin Phenotype












FN8.5.76 Skin CD8 1.7 0.1 18.1 1.1 14.7 1.2 94 26 30
FN8.5.1 Skin CD8 1.7 0.2 24.6 1.9 7.4 0.4 509 30 36
AC8.3.6 Skin CD8 1.0 0.04 25.4 0.5 19.8 0.1 906 35 32
AC8.5.3 Skin CD8 1.4 0.3 26.5 1.9 0.1 6.2 708 35 56
FN8.5.25 Blood CD8 0.6 0.09 9.1 0.85 7.3 0.9 608 25 34
AC8.5.59 Blood CD8 1.3 0.11 7.1 0.1 18.6 0.6 505 30 31
AR8.5.6 Blood CD8 0.8 0.01 8.9 0.94 7.6 1 101 34 31
AR8.5.8 Blood CD8 1.5 0.05 7.9 1.12 0.4 8.5 209 38 32
FN4.5.7 Skin CD4 2.4 0.01 40.4 1.94 8.4 0.7 205 26 26
FN4.5.20 Skin CD4 1.6 0.2 28.6 2.75 12.8 2.1 145 25 20
AC4.6.6 Skin CD4 2.3 0.41 30.3 0.5 10.5 0.3 290 30 21
AR4.1.43 Skin CD4 1.0 0.05 10.3 1.2 0.1 6.7 420 0 8
AC4.5.57 Blood CD4 2.4 0 39.6 0.96 19.6 0.1 85 29 21
FN4.5.29 Blood CD4 2.9 0.06 10.5 1.14 11 0.1 456 20 19
AR4.3.3 Blood CD4 0.9 0.04 9.9 1 0.1 5.2 345 0 9
AC4.6.14 Blood CD4 1.0 0.03 49.9 2.83 0.1 1.2 546 0 17
a Tcc were prepared from lesional skin or peripheral blood of patients with ACD to nickel. Resting Tcc were tested for Ag specificity after extensive washing to remove IL-2
and using irradiated autologous B-LCL in the presence or absence of 20 g/ml NiSO4. Data represent mean cpm SD of triplicate cultures.
b Tcc were stimulated with plate-coated anti-CD3 and soluble anti-CD28. After 48 h, supernatants were collected and cytokine content measured by ELISA. Data are expressed
as mean ng/ml/106 cells of triplicate cultures.
c Expression of CLA, perforin, and FasL was determined by flow cytometry on Tcc activated with immobilized anti-CD3 or B-LCL in the presence of 20 g/ml NiSO4. Data
are expressed as MFI, which represents the mean fluorescence intensity of positive staining subtracted of the fluorescence of isotype-matched Ig.
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moderately cytotoxic for B-LCL, showed no significant induction
of DNA cleavage in resting or IFN- -treated keratinocytes in the
presence of nickel (Fig. 3). However, Th2 cells could induce some
Ag-independent keratinocyte killing (10–15%) when the assay
was performed in the presence of PHA (data not shown). Pretreat-
ment of keratinocytes with both TNF- (50 g/ml) and IFN-
(300 U/ml) did not alter their susceptibility to the cytotoxicity
induced by CD8 or CD4 clones (data not shown).
IFN- -treated keratinocytes show lower MHC class I/II, ICAM-
1, and Fas expression, but higher Bcl-2 levels, compared with
B-LCL
As we observed important differences between B-LCL and kera-
tinocytes in the susceptibility to T cell-mediated cytotoxicity, we
compared the expression of molecules involved in Ag presentation
and cytotoxic pathways in these two target cells. As shown in Fig.
4, IFN- treatment induced de novo expression of MHC class II
and ICAM-1, strongly up-regulated MHC class I, and slightly en-
hanced Fas expression on keratinocytes. MHC class I and class II,
ICAM-1, and Fas showed higher expression on B-LCL than on
IFN- -stimulated keratinocytes, indicating a more efficient Ag pre-
sentation to specific Tcc and an enhanced susceptibility to Fas-
mediated killing. In contrast, the anti-apoptotic molecule Bcl-2
was markedly more expressed in both untreated and IFN- -stim-
ulated keratinocytes than in B-LCL (Fig. 4), helping to explain the
higher resistance of keratinocytes to apoptotic signals.
Heterogeneous killing pattern of nickel-specific CD4 and
CD8 clones
Two main cytolytic mechanisms are used by T cells, the perforin/
granzyme granule exocytosis and the Fas/FasL pathways (35, 36).
To examine which mechanism prevailed in our nickel-specific
clones, their cytotoxic activity was assessed in the presence of
different blocking agents. CMA is known to be a specific inhibitor
of the perforin pathway by altering the acidity of the lymphocyte
granules, thereby promoting premature degradation of perforin
(30). BFA preferentially affects the Fas/FasL pathway by prevent-
ing the egression of proteins from the endoplasmic reticulum and
thus inhibiting the up-regulation of FasL (30, 37). Furthermore, it
has been demonstrated that CMA and BFA affect exclusively ef-
fector, but not target, cells (30). Nickel-specific Tcc were prein-
cubated for 2 h with different concentrations of the blocking agent
and then used as effector cells against B-LCL in the [3H]TdR re-
lease assay. As shown in Fig. 5, the CTL activity of all CD8
clones was markedly inhibited by CMA. BFA significantly re-
duced the B-LCL killing of three (FN8.5.76, AR8.5.6, and
AC8.5.59) of six Tc1 clones, whereas it did not affect the Tc2
clones. With regard to the CD4 clones, CMA and BFA reduced
the cytotoxic capacity of three (AC4.6.6, FN4.5.20, and FN4.5.7)
and two (AC4.5.57 and FN4.5.29) Th1 clones, respectively. Fi-
nally, the Th2 clones were only inhibited by BFA. These results
indicated a preferential, but not exclusive, use of the granule exo-
cytosis pathway by nickel-specific CD8 clones and a heteroge-
neous pattern for CD4 clones, which showed either perforin- or
Fas-dependent cytotoxicity. As expected, preincubation of target
cells with anti-HLA-DR and MHC class I mAbs inhibited the cy-
totoxicity of CD4 and CD8 clones, respectively, ruling out an
unspecific cytotoxic effect (Fig. 5). Interestingly, the anti-ICAM-1
mAb strongly inhibited (50–60% reduction of specific killing) the
cytotoxic capacity of all nickel-specific CD4 clones and of those
three Tc1 clones (FN8.5.76, AR8.5.6, and AC8.5.59) affected by
BFA. In contrast, the remaining Tc1 and Tc2 clones were not
sensitive to ICAM-1 blocking. No significant differences in the
susceptibility of keratinocytes and B-LCL to the different T cell-
killing mechanisms were observed. As shown in Fig. 6, the killing
of two representative Tc1 and Tc2 clones was mostly inhibited by
CMA independently from the target cell type, confirming the prev-
alent, although not exclusive (FN8.5.76), use of the perforin path-
way. Th1 clones showed a disparate killing pattern also against
FIGURE 3. Th1 nickel-specific clones are cytotoxic for both B-LCL
and keratinocytes, whereas Th2 lymphocytes kill B-LCL, but not keratin-
ocytes. Target cells were B-LCL ( ), unstimulated keratinocytes ( ), and
IFN- -pretreated keratinocytes ( ). Cytotoxicity was determined using the
[3H]TdR release assay. Specific killing was calculated as described in Ma-
terials and Methods. Unspecific killing was always 3%.
FIGURE 4. IFN- -treated keratinocytes show lower MHC class I/II,
ICAM-1, and Fas expression and higher Bcl-2 levels compared with B-
LCL. FACS analysis of B-LCL and keratinocytes was performed before
and after treatment with IFN- . Expression in keratinocytes was assayed
48 h after stimulation with 300 U/ml IFN- . , Staining with matched-
isotype Ig; , cells stained with mAbs specific for the indicated markers.
The numbers indicate the net mean fluorescence intensity.






















keratinocytes and used either the perforin (AC4.6.6) or the Fas/
FasL pathway (AC4.5.57).
Perforin mRNA is expressed in lesional ACD skin
Our in vitro results indicated that CD8 T lymphocytes have a
prominent role in inducing keratinocyte apoptosis through a per-
forin-mediated mechanism. To investigate whether perforin was
expressed during the effector phase of ACD, 48-h positive patch
test reactions to nickel were analyzed by RT-PCR. Results showed
that perforin mRNA was indeed expressed in ACD skin (Fig. 7).
IFN- and IL-4 mRNA were also present in the lesional skin,
indicating the involvement of both type 1 and type 2 T lympho-
cytes in the immune reaction. In contrast, no perforin and IL-4 and
only a faint signal for IFN- mRNA were detected in healthy skin.
Discussion
In this study we show that skin-homing (CLA ) nickel-specific T
lymphocytes isolated from the skin and blood of patients with
ACD to nickel induced cytotoxicity in autologous keratinocytes in
vitro, suggesting an important pathway involved in the epidermal
damage during ACD. While CD8 T cells exerted their CTL ac-
tivity on both resting and IFN- -activated keratinocytes, Th1 cells
killed exclusively keratinocytes previously exposed to IFN- . The
mechanism by which CD4 and CD8 CTL lyse their targets has
important implications for their biological functions. The perforin/
granzyme pathway does not need the target cell to express specific
susceptibility molecules, and thus potentially allows lysis of all
cells (36). In contrast, the Fas/FasL mechanism requires the target
cell to express Fas and be sensitive to Fas-induced apoptosis (37).
Nickel-specific Tc1 and Tc2 clones expressed both perforin and
FasL upon activation, as described previously for CD8 T cells
with different Ag specificity (38 39). The cytotoxic activity of Tc1
and Tc2 clones against B-LCL and keratinocytes was inhibited by
CMA, confirming that the perforin pathway is a major killing
mechanism of CD8 T cells (40, 41). In contrast, BFA blocked
part of the Tc1 clones, but no Tc2 clones, indicating a minor, but
significant, involvement of the Fas/FasL killing pathway in the
CTL activity of some nickel-specific Tc1 clones. Our data also
showed that pretreatment of B-LCL with anti-ICAM-1 mAb af-
fected the Tc1 clones whose cytolytic functions were inhibited by
the FasL-blocking agent, BFA. In contrast, the Tc2 and Tc1 clones
that used only the perforin pathway were not influenced by
ICAM-1 blocking. This observation is in line with the hypothesis
that two types of CTL exist: type I CTL, which kill target cells
through the perforin/granzyme-dependent mechanism, and type II
CTLs, which require ICAM-1-derived signals to activate both Fas/
FasL and perforin-dependent pathways (38). Concerning the kill-
ing potential and machinery of CD4 T cells, contrasting results
have been described. Early reports on CD4 T cell-mediated cy-
totoxicity underlined that Fas was the major target molecule (42–
44), whereas recent studies revealed the importance of perforin-
dependent CD4 CTL, especially in the clearance of virus
infections and in tumor rejection (45– 47). Assessing this hypoth-
esis in our system, we found that nickel-specific Th1 clones ex-
pressed both perforin and FasL and could be inhibited by either
FIGURE 5. Nickel-specific CD4 and CD8 clones use disparate cy-
totoxic mechanisms. Tcc were preincubated for 2 h with various concen-
trations of CMA or BFA and then cocultured with B-LCL in the [3H]TdR
release assay, with the drug present during the assay. For blocking exper-
iments with the mAbs, target B-LCL cells were preincubated with the mAb
for 30 min at 4°C, and then cocultured with the effector cells. The exper-
iments were all performed at a target/effector cell ratio of 1:10. Each sym-
bol identifies a single nickel-specific Tcc.
FIGURE 6. Nickel-specific T cell clones use similar cytotoxic mecha-
nisms against B-LCL and keratinocytes. Tcc were preincubated for 2 h
with 0.2 M CMA or 50 M BFA and then cocultured with B-LCL or
keratinocytes (either resting or IFN- -activated) for 5 h in the [3H]TdR
release assay. The experiments were performed at a target:effector cell ratio
of 1:10.
FIGURE 7. Perforin mRNA is expressed in the lesional ACD skin. Skin
specimens were obtained from healthy skin and 48-h patch test reaction to
NiSO4 and subjected to RT-PCR analysis. Similar results were observed in
biopsies from two patients.
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CMA or BFA, pointing to a disparate killing pattern of Th1 cells
against both B-LCL and keratinocytes. In contrast, Th2 clones uni-
formly expressed FasL, but were consistently negative for per-
forin, and their killing capacity against B-LCL was regularly in-
hibited by BFA, but not CMA. In summary, our findings indicate
that heterogeneous populations of nickel-specific T cells can use
different cytotoxic modalities to eliminate the Ag-carrying cells.
Consistent with the idea that CTL have developed different strat-
egies to obviate virus-induced resistance to cytotoxicity (45, 46,
48), CTL can exploit the very same mechanisms during immune
responses to innocuous Ags, such as those inducing allergic dis-
eases. Indeed, studies in knockout mice have demonstrated that
perforin and Fas/FasL mechanisms are both necessary to mount
CH reactions (8).
Keratinocytes were highly susceptible to nickel-specific cyto-
toxicity induced by Tc1 and Tc2 cells and, to a lesser extent, by
Th1 cells, but were resistant to Th2 clones. However, Th1-medi-
ated killing required prior treatment of keratinocytes with IFN- .
Indeed, only keratinocytes stimulated with IFN- express mature
MHC class II molecules and ICAM-1 (17, 26). Moreover, IFN-
up-regulates Fas expression and renders keratinocytes susceptible
to Fas-mediated cytotoxicity (27, 49), which was shown to be in-
volved in Th1-mediated cytotoxicity. In contrast, IFN- treatment
had variable influences on the CD8 -mediated killing, with a sig-
nificant enhancement of the lytic capacity for those Tc1 clones
(FN8.5.76, AC8.5.59, and AR8.5.6) whose cytotoxicity was inhib-
ited by blocking ICAM-1. The cytotoxic activity of the other
CD8 clones was not significantly changed. The fact that CH re-
sponses in IFN- receptor-deficient mice are only partially affected
indicates a nonessential role for IFN- in these immune responses
(50). In contrast to our results, other studies indicated a higher lytic
activity of herpes virus-specific CD4 T cells compared with
CD8 lymphocytes against virus-infected keratinocytes (51). This
finding could be the consequence of reduced MHC class I expres-
sion on keratinocytes infected with the herpes virus. The disparate
cytotoxic activity of different T cell subsets against keratinocytes
suggests distinct roles in the effector phase of ACD, with CD8
lymphocytes killing resting keratinocytes, and Th1 cells exerting
cytotoxic functions only at later time points, when keratinocytes
have already been exposed to IFN- released by type 1 T cells.
An interesting observation of our study was that cultured kera-
tinocytes were, in general, more resistant than B-LCL to T cell-
mediated cytotoxicity. This different susceptibility may reflect the
higher expression of MHC, ICAM-1, and Fas on B-LCL as well as
the absence of B7-1 and B7-2 costimulatory molecules on kera-
tinocytes (52) (data not shown). In addition, keratinocytes ex-
pressed higher levels of the apoptosis-protective molecule Bcl-2,
although the role of Bcl-2 in protecting target cells against per-
forin/granzyme- and Fas/FasL CTL-induced apoptosis is still a
matter of debate (53–55). All nickel-specific Th2 clones were not
cytolytic against keratinocytes, but efficiently killed B-LCL target
cells through the Fas/FasL pathway. This may be an indication that
the cytotoxicity of Th2 clones has an immunoregulatory function
through the elimination of professional APC, as also proposed by
others (56).
The expression of ACD mostly depends on the recruitment and
expansion of hapten-specific CD8 T lymphocytes, as suggested
by studies in mice deficient in distinct T cell subsets (9–11) and in
the human disease (12–15). Our results clearly show that hapten-
loaded keratinocytes can be target of T cell-mediated cytotoxicity.
Hapten-specific CD8 T cells can exert direct cytotoxic effects on
resting keratinocytes, confirming their predominant role in the ini-
tiation of epidermal damage during ACD. Among CD4 T lym-
phocytes, only the Th1 subset was able to kill keratinocytes, but
exclusively after MHC class II induction by IFN- , and may thus
cooperate with CD8 T cells only at a later time point in causing
the tissue damage. In contrast, keratinocytes appear to be resistant
to Th2-mediated cytotoxicity. Alternatively, Th1 and Th2 cells can
effectively contribute to disease expression by inducing keratino-
cyte release of chemokines that attract T cells in the skin (17, 25)
and by rendering keratinocytes more susceptible to CTL activity.
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